Shots:

• The P-III PREPARE study involves assessing ResVax vs PBO in 4-636 pregnant women to prevent the risk of RSV Disease in infants
• PREPARE study results: didn’t met 1EPs @prevention of medically significant RSV LRTI; 39% against medically significant RSV LRTI; 44% against RSV LRTI hospitalizations; 48% against RSV LRTI with severe hypoxemia; reduction in LRTI  hospitalizations & hypoxemia (25% & 39%); vaccine efficacy against RSV LRTI hospitalization & hypoxemia@< 33wks. pregnancy (53%-70% vs 26%-44%)
• ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine used in combination with aluminum phosphate for prevention of severe LRTI in infants >1yrs.

Ref: Novavax | Image: Getty images